Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 106,506,192
  • Shares Outstanding, K 2,026,759
  • Annual Sales, $ 45,006 M
  • Annual Income, $ 8,025 M
  • 60-Month Beta 0.38
  • Price/Sales 2.35
  • Price/Cash Flow 4.17
  • Price/Book 3.58
Trade BMY with:

Options Overview Details

View History
  • Implied Volatility 21.81% ( -7.97%)
  • Historical Volatility 18.51%
  • IV Percentile 56%
  • IV Rank 37.78%
  • IV High 30.66% on 01/29/24
  • IV Low 16.43% on 06/16/23
  • Put/Call Vol Ratio 0.54
  • Today's Volume 32,650
  • Volume Avg (30-Day) 28,907
  • Put/Call OI Ratio 0.72
  • Today's Open Interest 572,321
  • Open Int (30-Day) 602,834

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate 1.53
  • Number of Estimates 9
  • High Estimate 1.75
  • Low Estimate 1.30
  • Prior Year 2.05
  • Growth Rate Est. (year over year) -25.37%

Price Performance

See More
Period Period Low Period High Performance
1-Month
50.28 +5.92%
on 02/29/24
55.03 -3.24%
on 03/13/24
+2.74 (+5.42%)
since 02/27/24
3-Month
47.58 +11.92%
on 02/06/24
55.03 -3.24%
on 03/13/24
+2.04 (+3.98%)
since 12/27/23
52-Week
47.58 +11.92%
on 02/06/24
71.07 -25.07%
on 04/06/23
-14.82 (-21.77%)
since 03/27/23

Most Recent Stories

More News
Next-Gen Cancer Therapies Could Spark Upside for AstraZeneca Stock

Next-generation cancer therapies are here. AstraZeneca - already an oncology leader - is going down the path of radiopharmaceuticals with its purchase of Fusion. Along with the other potential blockbuster...

AZN : 68.26 (+2.91%)
FUSN : 21.30 (unch)
NVS : 95.88 (+0.64%)
LLY : 778.18 (+0.42%)
BMY : 53.25 (+1.33%)
3 AI-Driven Drug Stocks to Buy Before They Breakout

The pharma sector is expected to undergo a huge disruption, thanks to the impact of artificial intelligence. Here are three companies that Wall Street analysts think could benefit, based on their AI-driven...

GOOGL : 150.87 (+0.13%)
AMZN : 179.83 (+0.86%)
GS : 415.25 (+2.23%)
BMY : 53.25 (+1.33%)
Got $5,000? These 3 Stocks Are Dirt Cheap Buys With Plenty of Upside

Shares of these companies are trading at sizable earnings discounts.

TPR : 46.68 (+2.80%)
PYPL : 66.57 (-0.15%)
BMY : 53.25 (+1.33%)
Is It Too Late to Buy These 2 Brilliant Passive Income Stocks?

Patience will be rewarded with these stocks.

PFE : 27.78 (+0.69%)
BMY : 53.25 (+1.33%)
Global Efforts Intensify to Address Surging Young Adult Colorectal and Anal Cancer Rates

USA News Group – Rates of cancer of the colorectal and anal regions have been on the rise for years in young adults, according to surgeons at Yale Medicine. As well, there are now alarming reports around...

ONCY : 1.0300 (+1.98%)
ONC.TO : 1.38 (unch)
TCRX : 8.30 (+3.88%)
BMY : 53.25 (+1.33%)
PDSB : 3.85 (-14.06%)
CCCC : 8.05 (+1.39%)
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NYSE:PFE),(NASDAQ:BTAI),(NYSE:BMY) EQNX::TICKER_END

ONCY : 1.0300 (+1.98%)
ONC.TO : 1.38 (unch)
EXEL : 23.86 (+1.06%)
PFE : 27.78 (+0.69%)
BTAI : 2.88 (+0.70%)
BMY : 53.25 (+1.33%)
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies

ONCY : 1.0300 (+1.98%)
ONC.TO : 1.38 (unch)
EXEL : 23.86 (+1.06%)
PFE : 27.78 (+0.69%)
BTAI : 2.88 (+0.70%)
BMY : 53.25 (+1.33%)
S&P 500 and Nasdaq 100 Climb to Record Highs on U.S. Economic Optimism

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is up +0.69%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.38%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.03%. Stock...

$SPX : 5,248.49 (+0.86%)
SPY : 523.17 (+0.84%)
$DOWI : 39,760.08 (+1.22%)
DIA : 397.56 (+1.20%)
$IUXX : 18,280.84 (+0.39%)
QQQ : 444.83 (+0.34%)
EMR : 113.45 (+1.34%)
CMG : 2,923.46 (-1.09%)
PANW : 282.26 (-1.55%)
CRWD : 322.25 (-2.35%)
FTNT : 67.27 (-0.27%)
ZS : 193.48 (-1.10%)
Pancreatic Cancer Treatments Poised for Major Advances in 2024

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:INCY),(NASDAQ:TNGX),(NASDAQ:RYZB),(NYSE:BMY) EQNX::TICKER_END

ONCY : 1.0300 (+1.98%)
ONC.TO : 1.38 (unch)
INCY : 57.12 (+1.01%)
TNGX : 7.70 (+2.53%)
BMY : 53.25 (+1.33%)
RYZB : 62.49 (+0.02%)
Bristol Myers Squibb (BMY) Q4 2023 Earnings Call Transcript

BMY earnings call for the period ending December 31, 2023.

BMY : 53.25 (+1.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers...

See More

Key Turning Points

3rd Resistance Point 54.52
2nd Resistance Point 54.10
1st Resistance Point 53.68
Last Price 53.25
1st Support Level 52.84
2nd Support Level 52.42
3rd Support Level 52.00

See More

52-Week High 71.07
Fibonacci 61.8% 62.09
Fibonacci 50% 59.32
Fibonacci 38.2% 56.55
Last Price 53.25
52-Week Low 47.58

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar